Skip to main content
← All verified funding
Tier AUS

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

National Institutes of Health

Sign in and complete your Funding Passport to see whether you qualify — a transparent, rule-based verdict, not a black box.

Sign In

About this opportunity

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Required documents

The official source lists no specific documents here — confirm requirements before applying.

Source & verification trail

First retrieved
November 20, 2026
Last verified
November 20, 2026
Content fingerprint
595c18a936f6d861…